文献速递垂体与肾上腺疾病

家族性肢端肥大症与垂体性巨人症的遗传学

Genetics of familial acromegaly and pituitary gigantism.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文综述家族性肢端肥大症和垂体性巨人症的遗传基础。具遗传基础的垂体腺瘤虽少但临床显著,生长激素腺瘤是常见亚型,胚系变异在家族性肢端肥大症家系及儿童青少年期GH高分泌表现为垂体性巨人症者中富集。已知遗传病因包括AIP等垂体腺瘤易感基因变异、Xq26.3微重复所致X连锁肢端肥大巨人症及GNAS合子后功能获得变异所致McCune-Albright综合征,新兴基因关联包括NF1、PRKACB、PAM和CHEK2;鉴于基因特异性治疗意义,需由经验丰富的垂体专科医生安排多模式基因检测并在专家级临床认证实验室进行,关键检测包括二代测序、染色体微阵列和微滴数字PCR,探索性研究基因检测可能有助于发现标准检测阴性者的新遗传病因。

要点

  • 家族性肢端肥大症和垂体性巨人症中生长激素腺瘤常见,胚系变异富集。
  • 已知病因包括AIP等易感基因变异、Xq26.3微重复和GNAS合子后变异。
  • 推荐由垂体专科医生安排多模式基因检测并在认证实验室进行。

核心结论

  • 具遗传基础的垂体腺瘤虽少但临床显著,生长激素腺瘤是常见亚型。
  • 家族性肢端肥大症和垂体性巨人症有明确遗传病因及新兴候选基因。
  • 基因特异性治疗意义需多模式基因检测全面评估遗传基础。

研究设计与样本

  • 综述,未报告检索范围与样本量。

主要发现

  • 胚系变异在家族性肢端肥大症家系及儿童青少年期GH高分泌表现为垂体性巨人症者中富集。
  • 已知遗传病因包括AIP、MEN1、CDKN1B、MAX和PRKAR1A变异,Xq26.3微重复所致X连锁肢端肥大巨人症,以及GNAS合子后功能获得变异所致McCune-Albright综合征。
  • 潜在关联包括NF1、PRKACB、PAM和CHEK2等新兴垂体腺瘤易感基因变异。

关键数值与推荐

  • 关键检测包括二代测序、染色体微阵列和微滴数字PCR。
  • 标准检测阴性者可考虑探索性研究基因检测以发现新遗传病因。

临床怎么用

  • 由经验丰富的垂体专科医生安排多模式基因检测。
  • 基因检测应在专家级临床认证实验室进行。
  • 考虑基因特异性治疗意义,需全面评估遗传基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The subset of pituitary adenomas with a heritable genetic basis is small but clinically striking. Somatotropinomas are amongst the most frequent pituitary adenoma subtypes encountered in this setting, with germline variants being enriched in familial acromegaly kindreds and people with a childhood or adolescent history of GH hypersecretion manifesting as pituitary gigantism. The genetic causes of familial acromegaly and pituitary gigantism include variants in established pituitary adenoma predisposition genes (AIP, especially, but also MEN1, CDKN1B, MAX, and PRKAR1A), X-linked acrogigantism due to Xq26.3 microduplications, and McCune-Albright syndrome due to postzygotic gain-of-function GNAS variants. Potential associations include variants in emerging pituitary adenoma predisposition genes, including NF1, PRKACB, PAM, and CHEK2. Given the potential for gene-specific therapeutic implications in these diseases, multimodal genetic testing arranged by experienced pituitary subspecialists and conducted in expert, clinically accredited laboratories is needed to fully evaluate the genetic basis of disease. Key investigations include next-generation sequencing, chromosome microarray, and droplet digital polymerase chain reaction. Exploratory research-based genetic testing may help uncover new genetic causes of familial acromegaly kindreds and pituitary gigantism in people with negative results on standard testing, benefiting those being tested as well as advancing our understanding of the heritable basis of somatotropinomas.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. De Sousa SMC, Daly AF. Genetics of familial acromegaly and pituitary gigantism. J Clin Endocrinol Metab. 2026. PMID: 41965096. doi:10.1210/clinem/dgag151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。